SLXP: Summary for Salix Pharmaceuticals, Ltd. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 3:40am EST - Canadian Markets open in 5 hours and 50 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Salix Pharmaceuticals Ltd. (SLXP)

On Feb 9: 26.97 USD 0.00 (0.00%)

MORE ON SLXP

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Salix Pharmaceuticals, Ltd. (NasdaqNM:SLXP) Delayed quote data

Last Trade:	26.97 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	26.97
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	8.50

Day's Range:	N/A - N/A
52wk Range:	6.14 - 29.91
Volume:	0
Avg Vol (3m):	838,210
Market Cap:	1.33B
P/E (ttm):	31.88
EPS (ttm):	0.85
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add SLXP to Portfolio

Download Data

HEADLINES

•	The Biggest Growth Stocks in Health Care
	at Minyanville.com (Thu, Jan 28)

•	Bulls On Board For A Big Run From Salix
	at Forbes.com (Tue, Jan 26)

•	Salix upgraded ahead of FDA's Xifaxan decision
	AP (Tue, Jan 26)

•	Salix Pharm upgraded by Oppenheimer
	Briefing.com (Tue, Jan 26)

•	Lightning Round: Boeing, Cadbury, Fifth Third Bancorp and More
	at CNBC (Fri, Jan 8)

•	Salix slapped with lawsuit over OsmoPrep
	at bizjournals.com (Wed, Dec 23)

•	Suits Commenced Against Maker of Prescription Cleansing Drug
	PRNewswire (Wed, Dec 23)

•	Salix to File for IBS Indication
	Zacks.com (Wed, Dec 16)

•	Salix, FDA discuss new drug application
	at bizjournals.com (Fri, Dec 11)

•	SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
	EDGAR Online (Thu, Dec 10)

•	Salix Pharmaceuticals Reports Concurrence with FDA on Content and Format of the Pending Rifaximin NDA in the Treatment of Non-Constipation Irritable B
	Business Wire (Thu, Dec 10)

•	SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Tue, Nov 24)

More Headlines for SLXP...

ANALYST

EPS Est (next year) (Dec-07) :	N/A
EPS Est (in 2 years) (Dec-08) :	0.11
Avg Rec (current)*:	3.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Salix Pharmaceuticals, Ltd. engages in acquiring, developing, and commercializing prescription drugs used in the treatment of various gastrointestinal diseases in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•